Leerink Partnrs Analysts Raise Earnings Estimates for ALNY

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Leerink Partnrs boosted their Q1 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will post earnings per share of ($0.72) for the quarter, up from their previous forecast of ($0.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($1.82) EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03).

Several other brokerages have also issued reports on ALNY. Scotiabank boosted their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday, March 31st. HC Wainwright reiterated a “buy” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Royal Bank of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday, March 21st. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a report on Friday, March 21st. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Trading Up 1.8 %

NASDAQ:ALNY opened at $234.56 on Friday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm’s 50 day moving average is $249.14 and its 200 day moving average is $257.07. The stock has a market capitalization of $30.51 billion, a PE ratio of -108.09 and a beta of 0.30.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Allworth Financial LP grew its stake in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the last quarter. Investment Management Corp of Ontario boosted its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after buying an additional 40 shares in the last quarter. Nixon Peabody Trust Co. grew its position in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares during the period. Brevan Howard Capital Management LP increased its stake in shares of Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Finally, IFP Advisors Inc lifted its position in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 47 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 over the last 90 days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.